# 2026-07443: FDA Greenlights Generics for Chewable Tadalafil Tablets

2026-07443, Determination That CHEWTADZY (Tadalafil) Chewable Tablets, 5 Milligrams, 10 Milligrams, 20 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-16; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-07443
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-07443
- Title: Determination That CHEWTADZY (Tadalafil) Chewable Tablets, 5 Milligrams, 10 Milligrams, 20 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 20464
- Published: 2026-04-16
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Greenlights Generics for Chewable Tadalafil Tablets

## Summary

The FDA has decided that CHEWTADZY chewable tablets (5, 10, and 20 mg) were not taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules. Patients and drug makers can expect more affordable options soon, with no safety worries holding things back.

## Abstract

The Food and Drug Administration (FDA or Agency) has determined that CHEWTADZY (tadalafil) chewable tablets, 5 milligrams (mg), 10 mg, 20 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for tadalafil, chewable tablets, 5 mg, 10 mg, 20 mg, if all other legal and regulatory requirements are met.

## Effects PRIA read

- Generic Approval Pathway Opens: benefit, medium. The FDA has officially found that CHEWTADZY (tadalafil) chewable tablets, 5 mg, 10 mg, and 20 mg, were not withdrawn from sale for safety or effectiveness. Because of that finding, abbreviated new drug applications (ANDAs) that refer to that listed drug (NDA 218527, held by B Better, LLC, initially…
- Possible Labeling Revision Requirement: cost, low. The FDA said that if it determines labeling for CHEWTADZY should be updated to meet current standards, the Agency will advise ANDA applicants to submit revised labeling. That means companies seeking to make a generic may need to change their product labeling to match FDA guidance before approval.
- FDA Found No Safety-Based Withdrawal: benefit, low. After reviewing the citizen petition (filed September 22, 2025), agency records, and postmarketing data, FDA determined CHEWTADZY chewable tadalafil tablets (5 mg, 10 mg, 20 mg) were not withdrawn for reasons of safety or effectiveness. The Agency reviewed the evidence and will continue to list the…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-07443 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/16/2026-07443/determination-that-chewtadzy-tadalafil-chewable-tablets-5-milligrams-10-milligrams-20-milligrams)
- [2026-07443 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-16/pdf/2026-07443.pdf)

## Related
- [Previous: 2026-07442, Termination of the Fast-Track for COVID-19-Related Appeals Pilot Program](https://policyrisk.com/federal-register/2026-07442)
- [Next: 2026-07444, Northern Natural Gas Company; Notice of Scoping Period Requesting Comments on E…](https://policyrisk.com/federal-register/2026-07444)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-07443 (as of 2026-06-08).
